Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. News
  7. Summary
    BIIB   US09062X1037

BIOGEN INC.

(BIIB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Biogen : to Report First Quarter 2021 Financial Results April 22, 2021

04/09/2021 | 07:38am EDT

Cambridge, Mass.- Biogen Inc. (Nasdaq:BIIB) today announced it will report first quarter 2021 financial results Thursday, April 22, 2021, before the financial markets open.

Following the release of the financials, the Company will host a live webcast with Biogen management at 8:00 a.m. ET. To access the live webcast, please go to the investors section of Biogen's website at http://investors.biogen.com/. Following the live webcast, an archived version of the call will be available on the website.

About Biogen
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics, and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer's disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology, and neuropathic pain.

We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media - Twitter, LinkedIn, Facebook, YouTube.

Contact:
Karen Jewell
Investor Relations
Biogen
781.464.2442

Disclaimer

Biogen Inc. published this content on 09 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 April 2021 11:37:01 UTC.


ę Publicnow 2021
All news about BIOGEN INC.
05/14SECTOR UPDATE : Health Care Stocks Rally Premarket Friday
MT
05/14BIOGENá : Topline Results From XLRP Phase 2/3 Study Miss Primary Endpoint
MT
05/14Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study for XLRP
GL
05/14BIOGENá : Phase 2/3 Study in X-Linked Retinitis Pigmentosa Didn't Meet Primary O..
DJ
05/13BIOGENá : and Envisagenics Announce Collaboration to Advance RNA Splicing Resear..
AQ
05/12BIOGENá : Exercises Option to Acquire Investigational Drug TMS-007 For Acute Isc..
MT
05/12Biogen Exercises Option to Acquire Investigational Drug TMS-007
DJ
05/12Biogen Announces Exercise of Option to Acquire the Investigational Drug TMS-0..
GL
05/11BIOGENá : Working With Capsigen to Develop Gene Therapies for CNS, Neuromuscular..
MT
05/10BIOGENá : and Capsigen Announce Collaboration to Discover and Develop Novel AAV ..
AQ
More news
Financials (USD)
Sales 2021 10 543 M - -
Net income 2021 2 084 M - -
Net Debt 2021 1 529 M - -
P/E ratio 2021 20,0x
Yield 2021 -
Capitalization 42 187 M 42 187 M -
EV / Sales 2021 4,15x
EV / Sales 2022 3,94x
Nbr of Employees 9 100
Free-Float 85,8%
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 33
Average target price 288,45 $
Last Close Price 280,21 $
Spread / Highest target 63,4%
Spread / Average Target 2,94%
Spread / Lowest Target -44,0%
EPS Revisions
Managers and Directors
NameTitle
Michel Vounatsos Chief Executive Officer & Director
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Chairman
Alfred W. Sandrock Executive Vice President-Research & Development
Mark Hernon Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN INC.14.44%42 187
CSL LIMITED-1.94%98 249
WUXI BIOLOGICS (CAYMAN) INC.2.63%57 290
SAMSUNG BIOLOGICS CO.,LTD.14.77%55 625
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.46.03%53 688
ALEXION PHARMACEUTICALS, INC.11.04%38 345